Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
February 24, 2026Cardiovascular DiabetologyOpen Access

Triglyceride glucose index—a body shape index (TyG-ABSI) outperforms traditional obesity indices in predicting all-cause and cardiovascular mortality in metabolic-dysfunction associated steatotic liver disease: the mediating role of biological aging

View Full Paper
Ask AI
Bookmark
Share

Authors

GYGuodong YangWHWenli HeXQXin Qiu

Discussion

Loading...

Member takes

Overview

This prospective cohort study shows that TyG-ABSI predicts mortality in MASLD, suggesting a new marker for risk assessment.

Key Points

  • This research aims to evaluate the predictive capability of the triglyceride glucose–a body shape index (TyG-ABSI) on all-cause and cardiovascular mortality in metabolic dysfunction-associated steatotic liver disease (MASLD).
  • Prospective cohort study with 7515 adults diagnosed with MASLD.
  • Defined MASLD using a Fatty Liver Index ≥ 60 with at least one cardiometabolic risk factor.
  • Conducted Kaplan-Meier survival curves and multivariable Cox regression analyses.
  • Performed mediation analysis to explore the role of biological aging.
  • TyG-ABSI showed higher predictive accuracy for mortality than traditional indices.
  • Among those in the highest TyG-ABSI quartile, the hazard ratios for all-cause and cardiovascular mortality were significantly elevated.
  • Mediation analysis indicated that biological aging played a significant role in the mortality risks.

Cite This Study

Yang et al. (2026) studied this question.

synapsesocial.com/papers/699d401ade8e28729cf651c4https://doi.org/10.1186/s12933-026-03112-4
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Prognostic effect of triglyceride glucose-related parameters on all-cause and cardiovascular mortality in the United States adults with metabolic dysfunction-associated steatotic liver disease2024 · 88 citations
  2. 2Association between triglyceride-glucose related indices and mortality among individuals with non-alcoholic fatty liver disease or metabolic dysfunction-associated steatotic liver disease2024 · 128 citations
  3. 3Triglyceride glucose-body mass index as a practical screening tool for metabolic dysfunction-associated steatotic liver disease in older adults: A community-based cohort study.2026
  4. 4Predictive significance of triglyceride-glucose index in forecasting adverse cardiovascular events among Type 2 diabetes mellitus patients with co-existing metabolic dysfunction-associated steatotic liver disease (MASLD): evidence from two cohort studies2026
  5. 5Association between triglyceride-glucose-frailty index and metabolic dysfunction-associated fatty liver disease: Mediation analysis involving obesity indicators in the NHANES2026